Pathos Put 6% Down on a Phase III ADC, and Alphamab Kept the Market It Can Actually Reach
Fresenius describes an end to end biopharma business. Dr. Reddy’s developed, made and filed this rituximab. Fresenius is only the channel.
By subject
Dr. Reddy’s Developed, Made and Filed the Rituximab. Fresenius Only Sells It.
Fresenius describes an end to end biopharma business. Dr. Reddy’s developed, made and filed this rituximab. Fresenius is only the channel.
The 340B Rebate Pilot Is Back at Under 5.5% of Sales, Rebuilt to Survive the Court That Killed It
HRSA restarted the 340B rebate pilot at under 5.5% of sales, wrapped in 21 pages of answers to the court that vacated the first one.
KKR’s 51.8% Premium for Integer Is Measured From Before the Company Said It Was for Sale
KKR’s 51.8% premium for Integer is struck to the day before Integer said it was for sale. The 28.8% is what a holder actually gained.
Indivior’s Holders Take 56.5% and $1 Billion, Supernus Takes the Name, the CEO and the Building
Indivior holders take 56.5% and a billion in cash. Supernus takes the name, the CEO and the building. Equals describes the board seats only.
Congress Exempted the Medically Frail. The Coding System Cannot Find Them.
Fewer than 500 of 10,000 rare diseases have an ICD-10 code. The Medicaid frailty exemption is verified against codes most patients never had.
The Biosimilar Was Too Cheap to Sell. So the Price Went Up Fourfold.
Byooviz relaunched in the US at an average sales price of $1,190, roughly four times its previous level and above the originator it references.
Washington Removed the Cushion Under Part D, and Handed the Auditors an Algorithm
Washington ended the subsidy holding Part D premiums down, charged a record number of Medicaid fraud defendants, and put prosecutors’ analytics inside CMS.
NICE Said Yes to the Lung Machine, and Then Attached Four Years of Conditions
NICE conditionally recommended the XVIVO perfusion system for NHS use, with four years of evidence generation and a hub model to end the postcode divide.
J&J Won the Ruling on 22 July. Five Days Later It Agreed to Pay $5.5 Billion.
J&J agreed to pay $5.5 billion to resolve roughly 76,000 ovarian talc claims, five days after a court ruling that put plaintiffs in an untenable position.